DataMEDS AI starts trading on Nasdaq under MEDS

DataMEDS AI began trading on the Nasdaq Capital Market under the new symbol MEDS on July 22, 2026, completing its rebrand from Wellgistics Health. The move comes as the Health IT company pushes ahead with acquisition and licensing transactions and promotes its AI and blockchain-based healthcare platforms.

Why it matters: - The symbol change gives DataMEDS AI a new market identity tied to its Health IT strategy. - The rebrand completes the transition from Wellgistics Health and may help investors connect the stock with the company’s data, pharmacy and telemedicine focus. - The company is still working through previously disclosed acquisition and licensing transactions, making the ticker change part of a broader reset.

What happened: - DataMEDS AI, Inc. began trading under the Nasdaq Capital Market symbol MEDS at the start of trading on Wednesday, July 22, 2026. - The company said the symbol change officially completed its corporate rebranding from Wellgistics Health, Inc., which traded as WGRX. - DataMEDS AI said it is a Health IT company using the EinsteinRx™ AI platform and the PharmacyChain™ blockchain-enabled smart contracts platform. - The company said it is focused on completing previously disclosed acquisition and licensing transactions.

The details: - DataMEDS AI says its model is built around a vertically aligned healthcare ecosystem that extends EinsteinRx into medical, laboratory and wearables applications. - The company said its Health Lives Here app is designed to support patient-specific solutions through blockchain-based data handling. - DataMEDS AI said it is initially targeting GLP-1-associated muscle loss and Long COVID patient bases. - The company said it intends to consolidate electronic health data into a proprietary health-centered blockchain infrastructure. - DataMEDS AI said that structure could let patients participate in data transaction revenue, reduce data friction for providers and support tailored clinical trial offerings. - The company also said the platform could support prescription drugs and proprietary nutraceutical products for patients pursuing specific health goals. - Interim Co-CEO Gerald Commissiong said the new symbol is expected to draw attention from the Health IT investment community. - Commissiong also said DataMEDS AI aims to help patients using prescription GLP-1 therapies and those with Long COVID through adjunct natural products and biometric data capture via the Health Lives Here app. - DataMEDS AI said it has 2,847,198 common shares outstanding. - Stockholders holding about 1,533,930 common shares, or a majority of the outstanding shares, are under lock-up agreements that block sales for at least 90 days from July 22, 2026. - The company said 919,465 common shares are currently deposited in DTCC and available for trading. - DataMEDS AI said no debt or preferred equity securities are currently eligible to convert into free-trading common shares. - The company said 80,826 cash warrants remain outstanding, with each warrant exercisable at $35.00 per share into free-trading common shares. - The company directed investors to its SEC filings for more information on capitalization and outstanding securities. - DataMEDS AI said it is a new B2i Digital Featured Company, with featured companies information available online.

Between the lines: - The company is tying the ticker change to a broader growth narrative around AI, blockchain, wearable data and patient engagement. - DataMEDS AI is also using market-size projections for blockchain healthcare, telemedicine, drone delivery and GLP-1 therapies to frame its opportunity set. - Those market references are forward-looking and do not guarantee adoption, revenue or shareholder returns. - The lock-up agreements and warrant structure suggest the company is still managing a tightly controlled share base.

What's next: - DataMEDS AI said it is continuing toward its acquisition and licensing pipeline. - The company’s forward-looking statements also point to possible changes involving the Pharmacy and Pharmacy Services division, potentially rebranded as Corexa Health. - The company said it is pursuing a proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors, subject to approvals and closing conditions. - DataMEDS AI said it will keep evaluating compliance with Nasdaq listing standards, liquidity needs and capital resources. - The company said investors should watch future SEC filings for updates on structure, securities and transaction progress.

The bottom line: - DataMEDS AI’s MEDS ticker launch is more than a cosmetic change. The company is using the rebrand to position itself as a data-driven healthcare platform while it works through a larger transaction and business integration plan.